IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer is a leading cause of cancer mortality worldwide.
• Interleukin-6 (IL-6) is a cytokine involved in cancer progression, including proliferation and apoptosis.
• The IL-6 -174G/C single nucleotide polymorphism (SNP) may affect IL-6 production and influence cancer outcomes.

Purpose of the Study:

• To investigate the association between the IL-6 -174G/C polymorphism and the clinical outcome in non-small cell lung cancer (NSCLC) patients.
• To determine if specific IL-6 genotypes correlate with survival rates in NSCLC.

Main Methods:

• DNA was extracted from peripheral blood of 424 NSCLC patients.
• IL-6 -174G/C genotypes were determined using PCR-RFLP (NlaIII).
• Genotypes were classified as high-producer (G carriers: CG/GG) or low-producer (CC) based on functional activity.

Main Results:

• Patients with G allele carrying genotypes (CG/GG) exhibited a statistically significant diminished survival (42.31 months) compared to patients with the CC genotype (62.79 months).
• The P-value for the survival difference was 0.032.
• Polymorphic variants in the IL-6 promoter region may alter transcription and consequently affect serum cytokine levels.

Conclusions:

• The IL-6 -174G/C genetic variant significantly impacts the prognosis of NSCLC patients.
• Carriers of the G allele in the IL-6 gene promoter are associated with poorer survival outcomes.
• This genetic marker could potentially aid in predicting NSCLC patient prognosis.